PT96916A - Processo para a preparacao de composicoes farmaceuticas contendo um macrolido - Google Patents

Processo para a preparacao de composicoes farmaceuticas contendo um macrolido

Info

Publication number
PT96916A
PT96916A PT96916A PT9691691A PT96916A PT 96916 A PT96916 A PT 96916A PT 96916 A PT96916 A PT 96916A PT 9691691 A PT9691691 A PT 9691691A PT 96916 A PT96916 A PT 96916A
Authority
PT
Portugal
Prior art keywords
macrolide
preparation
pharmaceutical compositions
immusuppreseive
chem
Prior art date
Application number
PT96916A
Other languages
English (en)
Other versions
PT96916B (pt
Inventor
Shigeo Nakanishi
Iwao Yamanaka
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of PT96916A publication Critical patent/PT96916A/pt
Publication of PT96916B publication Critical patent/PT96916B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
PT96916A 1990-03-01 1991-02-28 Processo para a preparacao de composicoes farmaceuticas contendo um macrolido PT96916B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5111090 1990-03-01

Publications (2)

Publication Number Publication Date
PT96916A true PT96916A (pt) 1991-11-29
PT96916B PT96916B (pt) 1998-07-31

Family

ID=12877668

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96916A PT96916B (pt) 1990-03-01 1991-02-28 Processo para a preparacao de composicoes farmaceuticas contendo um macrolido

Country Status (20)

Country Link
EP (1) EP0444659B1 (pt)
JP (1) JP2522121B2 (pt)
KR (1) KR0177158B1 (pt)
CN (1) CN1028961C (pt)
AT (1) ATE143598T1 (pt)
AU (1) AU642707B2 (pt)
CA (1) CA2037408C (pt)
DE (1) DE69122418T2 (pt)
DK (1) DK0444659T3 (pt)
ES (1) ES2093650T3 (pt)
GR (1) GR3021777T3 (pt)
HK (1) HK62797A (pt)
HU (2) HU209436B (pt)
IE (1) IE75221B1 (pt)
MX (1) MX9203032A (pt)
PT (1) PT96916B (pt)
RU (1) RU2028142C1 (pt)
SG (1) SG47986A1 (pt)
UA (1) UA51608C2 (pt)
ZA (1) ZA911502B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
US5147877A (en) * 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
PH30923A (en) * 1992-03-30 1997-12-23 American Home Prod Rapamycin formulation for iv injection.
AT408520B (de) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Galenische formulierungen
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US5516770A (en) * 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
JP4903568B2 (ja) 2003-08-29 2012-03-28 ベロクシス ファーマシューティカルズ エー／エス タクロリムスを含む固体分散体
AU2004267910B2 (en) 2003-08-29 2011-01-06 Veloxis Pharmaceuticals, Inc. Solid dispersions comprising tacrolimus
CN1765365B (zh) * 2004-09-29 2012-01-25 天马药业(集团)股份有限公司 提高苷或苷元类药物在胃内吸收的口服软胶囊
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
FR2879932B1 (fr) * 2004-12-27 2007-03-23 Aventis Pharma Sa Formulations injectable ou administrable par voie orale de derives d'azetidine
LT2167033T (lt) 2007-05-30 2017-08-10 Veloxis Pharmaceuticals A/S Kartą per dieną vartojama geriamoji vaisto forma, apimanti takrolimą
CL2008000374A1 (es) 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
CN101869547B (zh) 2009-04-24 2012-02-22 张娜 一种他克莫司注射制剂
PT2575769T (pt) 2010-02-17 2016-09-22 Veloxis Pharmaceuticals As Composição de tacrolímus estabilizada
WO2022187379A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions
CN115463097B (zh) * 2021-06-11 2024-04-19 杭州中美华东制药有限公司 一种他克莫司缓释中间体颗粒的制备工艺

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430455D0 (en) * 1984-12-03 1985-01-09 Fujisawa Pharmaceutical Co Fr-900506 substance
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
CH677448A5 (pt) * 1987-11-09 1991-05-31 Sandoz Ag
EP0350164A3 (en) * 1988-06-13 1991-07-24 Beecham Group Plc Amphotericin derivatives

Also Published As

Publication number Publication date
ZA911502B (en) 1991-12-24
ES2093650T3 (es) 1997-01-01
CA2037408A1 (en) 1991-09-02
JP2522121B2 (ja) 1996-08-07
EP0444659A2 (en) 1991-09-04
KR0177158B1 (ko) 1999-03-20
GR3021777T3 (en) 1997-02-28
RU2028142C1 (ru) 1995-02-09
DE69122418T2 (de) 1997-03-06
EP0444659A3 (en) 1991-12-18
AU7194991A (en) 1991-10-31
SG47986A1 (en) 1998-04-17
CA2037408C (en) 2002-12-17
HU209436B (en) 1994-06-28
HUT57043A (en) 1991-11-28
DK0444659T3 (da) 1996-11-18
EP0444659B1 (en) 1996-10-02
AU642707B2 (en) 1993-10-28
MX9203032A (es) 1992-07-31
CN1028961C (zh) 1995-06-21
HU211502A9 (en) 1995-11-28
HU910681D0 (en) 1991-09-30
IE75221B1 (en) 1997-08-27
HK62797A (en) 1997-05-16
PT96916B (pt) 1998-07-31
UA51608C2 (uk) 2002-12-16
DE69122418D1 (de) 1996-11-07
JPH04211012A (ja) 1992-08-03
KR910016336A (ko) 1991-11-05
CN1055110A (zh) 1991-10-09
ATE143598T1 (de) 1996-10-15
IE910679A1 (en) 1991-09-11

Similar Documents

Publication Publication Date Title
PT96916A (pt) Processo para a preparacao de composicoes farmaceuticas contendo um macrolido
MX9200817A (es) Derivados de piranil cianoguanidina y proceso para su preparacion.
PT99281A (pt) Processo para a preparacao de hidroximetil (metilenociclopentil) purinas e de hidroximetil (metilenociclopentil) pirimidinas
PT95852A (pt) Processo para a preparacao de agentes hipoglicemicos de oxazolidinediona
PT91602A (pt) Processo para a preparacao de compostos espiro com accao antibacteriana e de composicoes farmaceuticas que os contem
BR9305164A (pt) Composto, formulação farmacêutica e processo para preparar um composto
MX9300875A (es) Procedimiento para la preparacion de compuestos azabiciclicos.
DE69033069T2 (de) Prostaglandinanaloge
UY23318A1 (es) Procedimiento para la preparacion de derivados de heteroaroilo de antibioticos de beta lactama monociclicos
PT90725A (pt) Processo para a preparacao de novos compostos cefem
FI911138A (fi) Ny substituerad aminfoerening och foerfarande foer dess framstaellning.
ES2068497T3 (es) Derivados de urea, su produccion, y composiciones farmaceuticas que los contienen.
ES2155433T3 (es) Compuestos de 7-acil-3-(carbamoiloxi substituido) cefem, su utilizacion y procedimiento para su fabricacion.
PT80791B (pt) Processo para a preparacao de novas fenil-naftiridinas uteis nomeadamente como medicamentos anti-ulcerosos
BR9305752A (pt) Composto composiçao farmaceutica e processo para a preparaçao de um composto de derivados alquila da trazodona
BR9402148A (pt) Processo para a preparação da forma cristalina monohidratada de um composto, forma cristalina e composto
PT98186A (pt) Processo para a preparacao de purinil- e de pirimidinil-tetra-hidrofuranos e de composicoes farmaceuticas que os contem
PT92668A (pt) Processo para a preparacao de derivados de azabiciclo-heptano
BR9402149A (pt) Processo para a preparação da forma cristalina monohidratada de um composto
FI933928A (fi) Heteroarenylpiperaziner, foerfarande foer framstaellning av dessa och anvaendning som laekemedel
SE8200679L (sv) 1-bensyl-4-(4-(2-pyrimidinylamino) bensyl 1-2,3-dioxopiperazinderivat, salter derav, forfarande for framstellning derav och karcinostatiska medel der de ingar
PT84067B (pt) Processo de preparacao de novos derivados de pregnano
AU8292787A (en) Fluorine-containing macrolide compounds and their use
BR8804664A (pt) Processo para a preparacao de um composto e compostos

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19910930

FG3A Patent granted, date of granting

Effective date: 19980415

PC3A Transfer or assignment

Owner name: ASTELLAS PHARMA INC., JP

Effective date: 20060310

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20130415